Clinical Advances in Oncology

Gilberto Lopes, MD, editor-in-chief of the Journal of Global Oncology, Professor of Medicine, world renowned expert in lung cancer, and creator of a global oncology program at the University of Miami Sylvester Comprehensive Cancer Center, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other

Sumanta (Monty) Kumar Pal, MD, the youngest professor I have ever known and a GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more. Monty is an amazing researcher, mentor,

Gary Lyman, MD, MPH, Professor of Medicine and senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice. We discuss the many barriers to biosimilars uptake such as physicians’ education, their concerns about

David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of “Chasing My Cure,” discusses treating his own disease through experimental self-administered therapies, involvement in developing the first NCCN guidelines and FDA-approved drugs for Castleman disease, and how to effectively and systematically use off-label drugs for orphan diseases.

Matt Kalaycio, MD, a phenomenal leukemia specialist at the Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics. I recall the first presentation I have ever heard about Gleevec at a plenary session at ASH. Amazing

Toni Choueiri, MD, Professor of Medicine at Harvard Medical School, prolific researcher with hundreds of peer-reviewed articles in the most prestigious journals in the world, a kidney cancer specialist at the Dana-Farber Cancer Institute, and Director of the GU oncology program there, sits with me to discuss surgical considerations and multidisciplinary care for localized kidney

Aaron Gerds, MD, department of hematology and medical oncology, Cleveland Clinic, describes the benefits and pitfalls of Twitter as a platform for doctors to share their ideas and engage in the “ultimate peer-review process.” It’s fair to say that social media has transformed the way we communicate forever. So, what are the pluses and minuses

Ishwaria Subbiah, MD, MS, explains the value of having a dedicated team for oncology patient symptom management and demonstrates how using “supportive care” rather than “palliative care” can impact referrals. Palliative care is not well-integrated in Healthcare;thcare delivery. Why not? And what can be done to improve on this? Listen to an amazing physician, person,